Sionna Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
SION$3.57+8.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $58,451 | $37,788 |
| Marketable securities, current | 177,431 | 109,750 |
| Prepaid expenses and other current assets | 5,537 | 3,455 |
| Total current assets | 241,419 | 150,993 |
| Property and equipment, net | 2,225 | 2,466 |
| Marketable securities, noncurrent | 74,420 | 20,505 |
| Restricted cash | 963 | 962 |
| Operating lease right-of-use asset | 6,926 | 7,832 |
| Other assets | — | 2,994 |
| Total assets | $325,953 | $185,752 |
| Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $769 | $1,186 |
| Accrued expenses | 9,668 | 8,162 |
| Operating lease liability, current | 1,269 | 1,072 |
| Other current liabilities | 6 | — |
| Total current liabilities | 11,712 | 10,420 |
| Operating lease liability, noncurrent | 7,408 | 8,677 |
| Total liabilities | 19,120 | 19,097 |
| Commitments and contingencies (Note 8) | ||
| Series Seed convertible preferred stock, $0.001 par value, no shares and 3,963,963 shares authorized, issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | 13,014 |
| Series A convertible preferred stock, $0.001 par value, no shares and 5,704,161 shares authorized, issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | 25,235 |
| Series B convertible preferred stock, $0.001 par value, no shares and 11,370,621 shares authorized, issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | 110,791 |
| Series C convertible preferred stock, $0.001 par value, no shares and 18,628,970 shares authorized, issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | 181,328 |
| Total convertible preferred stock | — | 330,368 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value, 10,000,000 and no shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued or outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value, 500,000,000 and 55,200,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 44,723,585 and 4,798,721 shares issued, 44,723,585 and 4,722,763 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | 45 | 5 |
| Additional paid-in capital | 562,602 | 17,000 |
| Accumulated other comprehensive income | 540 | 368 |
| Accumulated deficit | (256,354) | (181,086) |
| Total stockholders’ equity (deficit) | 306,833 | (163,713) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $325,953 | $185,752 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.